The Hidden Dangers of Synthetic Alkaloids in Entheogenic Products

Introduction

The entheogenic community faces significant threats from synthetic alkaloids marketed under names that mimic natural mushrooms. One alarming case involves Diamond Shruumz, a product allegedly linked to severe health issues, including hospitalizations and seizures. This awareness article aims to raise public awareness about the dangers of these synthetic substances and the importance of rigorous testing to ensure safety.

Background

Synthetic alkaloids, while chemically similar to their natural counterparts, pose unique risks due to their high potency and unregulated nature. These substances are often marketed to evade standard drug detection methods, making them appealing yet dangerous. Recent incidents involving products like Diamond Shruumz underscore the severity of the issue.

The Diamond Shruumz Case

Dr. Jerome Cordova, a physician in Arizona, reported multiple patients experiencing severe symptoms after consuming Diamond Shruumz chocolates, including nausea, vomiting, seizures, and unconsciousness. Some patients required ventilation and ICU care. Dr. Cordova highlighted the lack of safety instructions on the product packaging and urged consumers to avoid these products .

In a press release, Arizona poison centers also issued warnings about Diamond Shruumz, citing similar cases of severe health issues and emphasizing the urgent need for consumer awareness and regulatory action . The FDA has initiated an investigation into the illnesses linked to these microdosing chocolate bars .

The Risk of Synthetic Alkaloids

Synthetic alkaloids like 4-ACO-DET (among others), are often found at very high concentrations (~99% purity), and pose a high risk of overdose, especially when compared to natural alkaloids, which typically have .8% – 2% potency. This increases the likelihood of toxicity due to mismeasured batches. The potency and variability of synthetic alkaloids make them particularly dangerous for unregulated production and consumption.

Industry Practices and Misleading Marketing

Products in the entheogenic market often use names and packaging that suggest natural origins but contain synthetic compounds. These “non-detect” alkaloids are designed to bypass drug tests, making them particularly dangerous as consumers remain unaware of the true nature of these products. Allegations surrounding products like Diamond Shruumz suggest they are marketed as safe, natural alternatives but may contain harmful synthetic ingredients. See: “Non-Detect Magic Mushrooms: A Loophole That Can Land You in Jail for 20 Years.”

Ensuring Safety

To address these risks, the Entheology Project is launching a national anonymous testing network this summer. This initiative will provide the public with access to testing kits and professional High-Performance Liquid Chromatography (HPLC) lab testing, ensuring the safety of entheogenic products. Testing is the only reliable way to verify the contents and potency of these substances.

Tips for Consumers:

1. Educate Yourself: Understand the differences between natural and synthetic alkaloids.
2. Use Testing Kits: Test products before use to verify their contents.
3. Purchase Wisely: Buy from reputable sources that offer transparency and proof of testing.
4. Report Issues: Report adverse effects to health authorities and organizations like the Entheology Project.

Conclusion

The rise of synthetic alkaloids in entheogenic products poses a grave threat to public health. Through education, rigorous testing, and informed purchasing decisions, consumers can protect themselves from these hidden dangers. The Entheology Project remains committed to promoting safety and awareness within the community.

TikTok Video:

@entheists

⚠️ WARNING: CONSUMER ALERT ⚠️ The Entheology Project is issuing an urgent warning about Diamond Shruumz mushroom chocolates and gummies. Reports have emerged of severe health issues, including nausea, vomiting, seizures, and unconsciousness, after consuming these products. Some cases have required hospitalization and ICU care. These products, often found in vape shops and gas stations, lack proper safety instructions and may contain dangerous synthetic alkaloids. Key Points: • Severe Health Risks: Multiple cases of severe reactions have been reported, including hospitalization. • Lack of Safety Information: Products lack adequate safety instructions and ingredient transparency. • Synthetic Alkaloids: These products may contain potent synthetic compounds that can be highly dangerous. How to Stay Safe: 1. Avoid Unknown Products: Do not consume products with unclear ingredients or insufficient safety information. 2. Report Adverse Effects: If you experience any adverse reactions, seek medical attention immediately and report the incident to health authorities. 3. Use Testing Kits: Only use entheogenic products that have been tested and verified for safety. The Entheology Project is launching a national anonymous testing network to provide reliable testing kits and lab services. Stay informed and protect your health. Full article: https://entheo.info/the-hidden-dangers-of-synthetic-alkaloids-in-entheogenic-products/ Disclaimer: The information in this warning includes references to a video by Dr. Cordova, a physician in Arizona, discussing the health risks associated with Diamond Shruumz products. The video details patient cases of severe reactions after consuming these products. For full context and more information, please view the original video on TikTok. Watch Dr. Cordova’s original video here: https://www.tiktok.com/@doctorcordova23/video/7379498146348617006 Note: The information presented in Dr. Cordova’s video and this warning is based on current reports and allegations and has not been proven in any court of law.

♬ original sound – entheism – entheists

Sources:

1. Dr. Cordova’s original TikTok video transcript detailing patient cases and concerns .
2. Arizona Poison Centers’ warnings and collaboration with FDA investigations .
3. The Rise of Synthetic Alkaloids in Unregulated Head Shops
4. Non-Detect Magic Mushrooms: A Loophole That Can Land You in Jail for 20 Years
5. 4-ACO Killed the Psilocybe Star: The Economic Divide in Entheogenic Treatment
6. FDA Investigation of Illnesses: Diamond Shruumz-Brand Microdosing Chocolate Bars (June 2024)
7. Diamond Shruumz Official Website
8. Banner Health Press Release on Diamond Shruumz
9. AZFamily Report on Diamond Shruumz Illnesses
10. USA Today Article on Diamond Shruumz Illnesses

4-ACO-DMT Shortage Leads to New Knockoffs – Mushroom Prices Plummet!

The entheogenic market is currently undergoing a significant transition, underscored by the contrasting production costs and efficiencies between organic mushroom extracts and synthetic alternatives like 5-AcO-DET. For example, producing a 25mg psilocybin-infused chocolate bar using organic extracts, with a mere 2% potency, incurs an approximate cost of $12.40, largely due to the considerable volume needed to achieve the desired dose. In contrast, the utilization of 5-AcO-DET, boasting a 99.5% purity, dramatically reduces the cost per bar to around $2.25, not only demonstrating the economic advantage but also highlighting the potential for enhanced consistency and dosage control. This stark disparity underscores a broader market inclination towards synthetic entheogens, propelled by their cost-effectiveness, potency, and the pursuit of standardized therapeutic outcomes, marking a pivotal moment for both producers and consumers within the psychedelic sphere.

In the ever-evolving landscape of psychedelic substances, a notable trend is the burgeoning shift towards synthetic alternatives, exemplified by compounds like 4-AcO-DET. This movement, while fostering interest, also stirs concerns among both enthusiasts and scholars. Natural psilocybin, derived from mushrooms, has been lauded for its therapeutic potential—a sentiment echoed by research in Molecular Psychiatry, which demonstrates its efficacy in psychiatric therapy. However, synthetic alkaloids are carving a niche for themselves, distinguished by their ease of access and ambiguous regulatory status. This dichotomy between synthetic psilocybin and natural mushroom extract is further highlighted by their distinct impacts on brain proteins linked to learning and memory, with mushroom extract demonstrating a more profound and enduring effect. Moreover, the unique influence on brain metabolism hints at a divergence in how each variant modulates stress and energy pathways, suggesting that natural extracts may offer supplementary benefits over their synthetic counterparts and inviting more in-depth investigation into these distinctions.

Amidst this shifting landscape, the dialogue surrounding synthetic versus organic alkaloids centers on aspects of purity, effect predictability, and therapeutic value. Synthetics, with their promise of controlled dosage and broader accessibility, nevertheless lack the intricate array of compounds present in natural sources, which might play a crucial role in the holistic therapeutic experience. This ongoing debate accentuates the imperative for further research into both synthetic and natural psychedelics to fully comprehend their potential and implications for mental health treatments.

Complicating the narrative of psychedelic research and usage is the emergent concern over unregulated head shops. These entities, often navigating through legal gray areas, have become key distributors of novel substances like 4-AcO-DET, exploiting the compound’s elusive status to circumvent established regulatory frameworks. This scenario not only hinders efforts to safeguard the quality and safety of psychedelic substances but also rings alarm bells over the ease of access to these powerful compounds, especially for minors. The absence of rigorous oversight and standardized testing protocols opens the door to the potential misuse of psychedelics, underscoring the pressing need for comprehensive policies that tackle the sale and distribution of novel psychoactive substances while prioritizing public health and safety.

Engaging with the black market for entheogens, encompassing both organic and synthetic psychedelics, introduces formidable risks that extend beyond mere legal implications. The recent debacle involving the Incognito darknet market, as detailed by Krebs on Security, starkly illustrates the inherent perils. Following an “exit scam” by its administrators, which saw them absconding with millions in cryptocurrency, they proceeded to mass-extort users, threatening to disclose sensitive transaction and chat logs unless a ransom was paid. This alarming scheme puts countless users in jeopardy, exposing them to potential legal repercussions, privacy violations, and personal harm. Such incidents vividly showcase the hazardous realities of navigating the black market, emphasizing the need for caution and highlighting the darker facets of accessing entheogens outside sanctioned and regulated channels. To gain a more comprehensive insight into this incident, consulting the article on Krebs on Security is highly recommended.

The debate between synthetic and organic alkaloids revolves around purity, the predictability of effects, and therapeutic value. Synthetics, while offering a controlled dosage and easier accessibility, lack the complex array of compounds found in natural sources, which may contribute to the overall therapeutic experience. This discussion underscores the need for more research into both synthetic and natural psychedelics to understand their full potential and implications for mental health treatments. Amidst the evolving landscape of psychedelic research and use, the role of unregulated head shops has emerged as a significant concern. These establishments, often operating in legal gray areas, have become conduits for the distribution of new substances like 4-AcO-DET, leveraging the compound’s “non-detectable” status to bypass existing regulatory frameworks. This situation not only complicates efforts to ensure the safety and quality of psychedelic substances but also raises alarms about the accessibility of these potent compounds to minors. Without stringent oversight and standardized testing protocols, unregulated head shops can inadvertently contribute to the misuse of psychedelics, underscoring the urgent need for comprehensive policies that address the sale and distribution of novel psychoactive substances while protecting public health and safety.

The shift from 4-AcO-DMT to 4-AcO-DET in the production of psychedelic substances can also be attributed to operational risks encountered by manufacturers. Specifically, the crackdown on the precursor chemicals required for synthesizing 4-AcO-DMT, marked by significant legal actions including busts, has made these precursors “flagged” and monitored more closely by authorities. This heightened scrutiny led those involved in the large-scale production of 4-AcO-DMT to halt their operations, seeking alternative compounds that could circumvent these new challenges.

In this context, 4-AcO-DET has become the compound of choice for several reasons. It shares a very similar psychoactive profile with 4-AcO-DMT, offering comparable effects and dosages, which makes it an attractive alternative for both producers and users seeking similar experiences. However, a key advantage of 4-AcO-DET lies in its current status regarding drug testing methodologies, particularly High-Performance Liquid Chromatography (HPLC). Due to the lack of established standards for 4-AcO-DET, it does not show conclusive results on HPLC screenings, making it more difficult to detect and therefore more appealing for clandestine production. This transition reflects a strategic shift within the psychedelic substance market, driven by the desire to continue operations amidst increasing regulatory pressures and the evolving landscape of drug enforcement and detection.

Understanding Non-Detectable Psilocybin Analogues:Non-detectable psilocybin analogues, like 4-AcO-DET, are synthetic compounds that mimic the effects of psilocybin, the psychoactive ingredient in certain species of mushrooms. 4-AcO-DET stands for 4-Acetoxy-N,N-diethyltryptamine, a molecule closely related to psilocybin and psilocin (the compound into which psilocybin is converted in the body). These analogues are considered “non-detectable” due to the current limitations in drug testing technology, which often do not include specific standards for identifying these newer synthetic compounds.

The Chemistry and Effects of 4-AcO-DET: 4-AcO-DET features a chemical structure with an acetoxy group attached to the indole ring of the tryptamine backbone, similar to psilocin. This structural similarity suggests that 4-AcO-DET acts as a prodrug to ethocin, thereby producing effects similar to those of psilocybin. Users of 4-AcO-DET report experiences of euphoria, visual hallucinations, altered perception of time and space, and profound changes in thought and emotion, which closely parallel the psychedelic experience induced by psilocybin mushrooms.

Shift in Production from 4-AcO-DMT to 4-AcO-DET:For those recently familiarizing themselves with the psychedelic compound 4-AcO-DMT, it’s noteworthy that its production has significantly dwindled. This change came about as the precursors for 4-AcO-DMT were flagged following a high-profile bust, causing producers to pivot towards synthesizing 4-AcO-DET instead. 4-AcO-DET, while offering the same psychedelic effects and dosages as 4-AcO-DMT, remains challenging to detect using High-Performance Liquid Chromatography (HPLC) due to the lack of a standardized testing method. However, users should note that 4-AcO-DET has a slightly more bitter taste, necessitating adjustments in formulations, such as the addition of bitter blockers in edibles.

Challenges and Considerations: The classification of 4-AcO-DET and similar compounds as “non-detectable” raises important considerations regarding safety, legality, and research. The absence of standardized tests for these substances complicates efforts to understand their full pharmacological profile, potential risks, and therapeutic benefits. Moreover, the legal status of such compounds can vary significantly across different jurisdictions, often lagging behind the pace of new substance development and discovery.

The therapeutic potential of these analogues, mirroring that of psilocybin, opens up new avenues for research into mental health treatments. However, the novelty and variability of these compounds necessitate a cautious approach, emphasizing the importance of controlled studies to elucidate their efficacy, safety, and mechanisms of action.

The exploration of non-detectable psilocybin analogues like 4-AcO-DET represents a fascinating frontier in psychedelic research, offering both challenges and opportunities. While these substances promise to expand our understanding of psychedelic pharmacology and its potential applications, they also underscore the need for advancements in detection methodologies, regulatory frameworks, and scientific research. As we continue to investigate these compounds, a balanced approach that considers both their potential benefits and risks will be crucial in harnessing their full potential.

Sources:

1. 4-AcO-DMT by Albert Hofmann And Franz Troxler
2. Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain
3. Mushroom Extract Outperforms Synthetic Psilocybin in Psychiatric Therapy
4. Incognito Darknet Market Mass-Extorts Buyers, Sellers

Is Sublingual Psilocin the Next Leap in Entheogenic Therapy?

 Summary: 

• Sublingual psilocin is becoming a preferred method for its potential to provide consistent effects and reduce gastrointestinal discomfort compared to oral consumption of psilocybin mushrooms.
• The method involves placing psilocin under the tongue for direct bloodstream absorption, addressing issues of unpredictable potency.
• Users should begin with low doses to gauge personal tolerance and response.
• A safe and controlled setting is critical, along with the presence of a sober, experienced guide.
• Prior medical consultation is advised, particularly for those with mental health conditions or taking other medications.
• Awareness and adherence to legal restrictions regarding psilocybin and psilocin are necessary.
• While promising, sublingual psilocin must be approached with caution and responsibility to ensure safe and positive experiences.

Introduction

The emerging field of entheogenic facilitation has witnessed the advent of sublingual psilocin as a novel method for administering the active compound found in psilocybin mushrooms. This technique, which entails placing the substance beneath the tongue to allow for direct absorption into the bloodstream, is becoming increasingly favored for its potential to mitigate inconsistent potencies and gastrointestinal disturbances often associated with traditional consumption. Yet, alongside its benefits, sublingual psilocin brings forth critical safety and responsible usage concerns that require attention.

Irregular Potency and GI Side Effects of Mushrooms

Users of psilocybin mushrooms often encounter unpredictable variations in strength, complicating the ability to foresee the intensity of the resulting entheogenic state. Such unpredictability can culminate in unexpectedly potent experiences or a complete lack thereof, which can lead to a sense of isolation or disappointment during group sessions.

Furthermore, ingesting psilocybin mushrooms can provoke gastrointestinal discomfort, including nausea, vomiting, and abdominal pain, detracting from the user’s overall experience and focus during the entheogenic journey.

The Sublingual Psilocin Solution

Sublingual psilocin has the potential to overcome these hurdles. By circumventing the digestive system, it promises a reduction in gastrointestinal side effects. Additionally, its direct entry into the circulatory system could offer more uniform and reliable effects, presenting an intriguing alternative for those seeking a consistent entheogenic experience.

Harm Reduction Points for Sublingual Psilocin

1. Dosage: Initial doses should be conservative to gauge individual reactions to sublingual psilocin. Remember that additional doses can be taken, but the effects of an excessive initial dose cannot be reversed.
2. Set and Setting: The importance of a secure, tranquil environment surrounded by trusted individuals cannot be overstated, as both mental state and setting are pivotal to the entheogenic experience.
3. Supervision: Whenever feasible, the presence of a sober, knowledgeable guide is advisable to assist with any demanding experiences that may arise.
4. Health Considerations: Prior to engaging with sublingual psilocin, consulting a healthcare professional is crucial, particularly for those with mental health histories or those on concurrent medications.
5. Legal Considerations: Awareness of the legal context surrounding psilocybin and psilocin in one’s region is essential. Despite the burgeoning recognition of their therapeutic promise, these substances remain under legal scrutiny and are prohibited in numerous jurisdictions.

Conclusion

As a contemporary alternative to psilocybin mushrooms, sublingual psilocin extends the possibility of more predictable and smoother entheogenic experiences. Nevertheless, its responsible application and the cognizance of associated risks are paramount for a secure and enriching encounter. Adhering to harm reduction principles ensures the well-being and positive outcomes for those exploring the depths of sublingual psilocin therapy.

References

1. Johnson, M., Richards, W., Griffiths, R., 2008. Human hallucinogen research: guidelines for safety. J. Psychopharmacol. 22 (6), 603 – 620.
2. Johnson, M.W., Griffiths, R.R., Hendricks, P.S., Henningfield, J.E., 2018. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
3. Johnson, M.W., Hendricks, P.S., Barrett, F.S., Griffiths, R.R., 2019. Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol. Ther. 197, 83 – 102.
4. Lamb, R.J., Griffiths, R.R., 1987. Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon. Psychopharmacology (Berl) 91 (3), 268 – 272.
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813425/
6. 1-s2.0-S0028390822002799-main.pdf, p. 17, pos. 166
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602275/
8. lsdmyproblemchild.pdf, p. 57, pos. 44

The Power of GABA and Amanita Mushrooms in Shaping Depression, Sleep, Mood and Anxiety

In this illuminating exploration into the shifting sands of mental health research, the focus moves away from serotonin to the emerging importance of Gamma-aminobutyric acid (GABA) and muscimol ¹. The article delves into how these molecules regulate mood, sleep, and anxiety, thereby challenging existing paradigms ^2-3. From discussing natural ways to enhance GABA’s effects to investigating the untapped potential of muscimol, this comprehensive guide stands at the cusp of a transformative shift in mental health understanding ^4-5. The article advocates for a cautious, evidence-based approach, acknowledging that these are early yet promising days in neuroscience.

The Role of GABA and Its Importance

There’s a growing consensus that GABA may be as important as serotonin in understanding conditions like depression. GABA serves as the brain’s calming agent, and imbalances can lead to a range of neurological issues:

• Anxiety Disorders: Associated with GABA imbalances ⁸.
• Sleep Disturbances: GABA is key in sleep regulation ⁹.
• Mood Disorders: Fluctuations in GABA levels can affect mood ¹⁰.
• Cognitive Impairment: GABA influences cognitive functions like memory ¹¹.
• Pain Perception: GABA modulates pain sensitivity ¹².

GABA’s role is complex, and it’s just one piece of a larger puzzle.

Natural Ways to Enhance GABA

GABA is found in foods like tomatoes and white tea and can be boosted through various strategies:

• Meditation and Mindfulness: Increases GABA levels ⁴.
• Exercise: Activities like yoga may enhance GABA ³.
• Supplements: Substances like L-theanine can support GABA ⁵.
• Herbal Remedies: Traditional herbs may boost GABA ¹⁵.
• Stress Management: Methods to handle stress can aid GABA ⁶.
• Sleep Hygiene: Proper sleep supports GABA ⁷.

Muscimol: The Newcomer on the Block

Muscimol, a derivative of Amanita pantherina mushrooms, is garnering attention for:

• Alcohol Alternatives: Due to its GABA agonist properties ⁸.
• Anxiety Management: Shows promise for anxiety relief ⁹.
• Potential Antidepressant: Interacts with the GABA system ¹⁰.
• Neuroprotection: Promotes brain health ¹¹.

Benefits of Muscimol Over Alcohol

1. Liver Health: One of the most significant advantages is the reduced strain on the liver, as muscimol doesn’t have the toxic effects commonly associated with alcohol.
2. Cognitive Function: Unlike alcohol, which can impair cognitive abilities and decision-making, muscimol has shown promise in potentially enhancing certain cognitive functions.
3. Caloric Intake: Alcohol is notoriously high in empty calories, contributing to weight gain. Muscimol has no such effect, making it a better choice for those conscious of their weight.
4. Reduced Risk of Addiction: While further research is needed, early indications suggest that muscimol may have a lower potential for abuse and addiction compared to alcohol.
5. Social Ease: An intriguing benefit of muscimol is its potential to facilitate easier social interactions, without the negative repercussions often associated with alcohol, such as aggression or impaired judgment.

Precautions and Future Research

It’s worth noting that while muscimol presents an exciting alternative to alcohol, it is a potent compound that requires responsible use and further study. The long-term effects are not yet fully understood, and it’s advisable to consult healthcare professionals before making any changes to your lifestyle or treatment plan.

By exploring healthier alternatives like muscimol, we may be taking a significant step toward a future where socializing and relaxation can be achieved without compromising our long-term health.

References and Sources

1. Frontiers in Neuroscience 2020; 14: 923
2. Cleveland Clinic, GABA
3. Neuropharmacology January 2012; 62(1): 42-53
4. Psychotherapy and Psychosomatics September 14, 2017
5. Big Think September 25, 2017
6. Molecular Psychiatry July 20, 2022 DOI: 10.1038/s41380-022-01661-0
7. Haidut.me August 1, 2023
8. WSJ July 28, 2023
9. ZeroHedge July 31, 2023
10. http://haidut.me/?p=2302
11. krediet-et-al-ijnp-2020.pdf, p. 13, pos. 298
12. Molecular Psychiatry July 20, 2022 DOI: 10.1038/s41380-022-01661-0
13. WSJ July 28, 2023
14. ZeroHedge July 31, 2023
15. The BMJ 20155; 350: h2435